Investigating the Link Between Immunosuppressive Drugs and Cancer Risk in Transplant Patients

Strategic Insights -

Recent research conducted at the University of Texas Medical Branch has shed light on the connection between prolonged use of immunosuppressive drugs and an increased risk of cancer in transplant patients. A team of investigators studied the risk of cancer associated with five commonly used immunosuppressive drugs: tacrolimus, cyclosporin, sirolimus, mycophenolate, and their combinations, among 7721 transplant recipients in Texas Medicare beneficiaries between 2007 and 2018. The study found a significant correlation between the use of these drugs and the development of various types of cancer.

Key Takeaways:

  • The use of tacrolimus (TAC) was associated with an increased risk of any cancer diagnosis, with a hazard ratio (HR) of 1.49 (95% CI: 1.25-1.78).
  • Cyclosporin (CY) use was also linked to an increased risk of any cancer diagnosis, with an HR of 1.51 (95% CI: 1.19-1.92).
  • Mycophenolate (MMF) use was associated with a decreased risk of any cancer diagnosis, with an HR of 0.77 (95% CI: 0.67-0.89).
  • The study found increased risk of liver cancer (HR: 5.25, 95% CI: 2.03-13.61) and decreased risk of ovarian/uterine cancer (HR: 0.25, 95% CI: 0.07-0.84) with TAC use.
  • Cyclosporin use was linked to an increased risk of lung cancer (HR: 5.06, 95% CI: 1.47-17.41).
  • Sirolimus (SIR) was associated with an increased risk of lymphoma (HR: 2.80, 95% CI: 1.00-7.81).

Statistics:

  • 7721 transplant recipients were studied.
  • 2261 of the transplant recipients developed cancer.
  • The study period was from 2007 to 2018.
  • The population studied consisted of Texas Medicare beneficiaries.

Sources:

  • Cancers, 2025;17(13):2161. (Immunosuppressant Drug Specific Risk of Malignancy After Organ Transplantation: a Population-based Analysis of Texas Medicare Beneficiaries)
  • NewsRx. University of Texas Medical Branch Reports Findings in Liver Cancer (Immunosuppressant Drug Specific Risk of Malignancy After Organ Transplantation: a Population-based Analysis of Texas Medicare Beneficiaries). Cancer Weekly. August 5, 2025; p 82.